AlxplorerBio and AliveX, BIOCAST Reached a Strategic Collaboration Agreement, To Jointly Promote the Development of Precision Medicines of IBD

News

Home / News / Portfolio Highlights / Portfolio Highlights detail

Time: 2021-12-30

Source: Viva Biotech

[Abstract]:The collaboration integrates the strengths of the three companies to jointly promote the development of precision medicines of IBD, preclinical studies, and IND enabling in China and the U.S.

Shanghai, China - December 23, AlxplorerBio, invested and incubated by Viva BioInnovator, announced that a strategic collaboration with AliveX and BIOCAST(invested and incubated by Viva BioInnovator) to promote the development of precision medicines of Inflammatory Bowel Disease (IBD). The collaboration integrates the strengths of the three companies to jointly promote the development of precision medicines of IBD, preclinical studies, and IND enabling in China and the U.S.

Previous Page：ABM Therapeutics Completes $30 Million Series B Financing Next Page：Portfolio Highlights: Clinical and Financing Updates of VivaVision, QureBio, AlxplorerBio and BIOCAST

Back

Media contact: vivapr@vivabiotech.com